Stock Events

Stock Events

Plus Therapeutics 

$0.16
206
-$0.06-28.05% Today

Statistics

Day High
0.16
Day Low
0.14
52W High
-
52W Low
-
Volume
427,455
Avg. Volume
-
Mkt Cap
21.76M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16AprExpected
Q3 2025
Next
-0.04
-0.03
-0.03
-0.02
Expected EPS
-0.0325
Actual EPS
N/A

Financials

-222.84%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
11.65MRevenue
-25.96MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 19.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PSTV.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mustang Bio
MBIO
Mkt Cap10.5M
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focusing on cell and gene therapies for cancer, directly competing with Plus Therapeutics.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG is known for its gene-editing technology applied in cancer therapy, which competes with Plus Therapeutics' approach to cancer treatment.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders, competing with Plus Therapeutics' focus.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics, Inc. works on allogeneic CAR T therapies for cancer, a direct competitor to Plus Therapeutics' cancer treatment efforts.

About

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Show more...
CEO
ISIN
US72941H5090

Listings

F
DE
XMP0.F
XNAS
US
PSTV
BOATS
BOATS
PSTV.BOATS

0 Comments

Share your thoughts

FAQ

What is Plus Therapeutics stock price today?▼
The current price of PSTV.BOATS is $0.16 USD — it has decreased by -28.05% in the past 24 hours. Watch Plus Therapeutics stock price performance more closely on the chart.
What is Plus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Plus Therapeutics stocks are traded under the ticker PSTV.BOATS.
What is Plus Therapeutics market cap?▼
Today Plus Therapeutics has the market capitalization of 21.76M
When is the next Plus Therapeutics earnings date?▼
Plus Therapeutics is going to release the next earnings report on April 16, 2026.
What were Plus Therapeutics earnings last quarter?▼
PSTV.BOATS earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.02 USD resulting in a -100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Plus Therapeutics revenue for the last year?▼
Plus Therapeutics revenue for the last year amounts to 11.65M USD.
What is Plus Therapeutics net income for the last year?▼
PSTV.BOATS net income for the last year is -25.96M USD.
When did Plus Therapeutics complete a stock split?▼
Plus Therapeutics has not had any recent stock splits.